Literature DB >> 28696171

Multiple Sclerosis-Associated Uveitis.

Emmett T Cunningham1,2,3, Carlos E Pavesio4, Debra A Goldstein5, Farzin Forooghian6, Manfred Zierhut7.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28696171     DOI: 10.1080/09273948.2017.1334469

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


× No keyword cloud information.
  5 in total

1.  Uveitis prior to clinical presentation of Multiple Sclerosis (MS) is associated with better MS prognosis.

Authors:  Eyal Raskin; Anat Achiron; Ofira Zloto; Ron Neuman; Vicktoria Vishnevskia-Dai
Journal:  PLoS One       Date:  2022-06-29       Impact factor: 3.752

Review 2.  A Comprehensive Update on Retinal Vasculitis: Etiologies, Manifestations and Treatments.

Authors:  Aniruddha Agarwal; Anne Rübsam; Lynn Zur Bonsen; Francesco Pichi; Piergiorgio Neri; Uwe Pleyer
Journal:  J Clin Med       Date:  2022-04-30       Impact factor: 4.964

3.  Targeting CD6 for the treatment of experimental autoimmune uveitis.

Authors:  Lingjun Zhang; Yan Li; Wen Qiu; Brent A Bell; Nina Dvorina; William M Baldwin; Nora Singer; Timothy Kern; Rachel R Caspi; David A Fox; Feng Lin
Journal:  J Autoimmun       Date:  2018-02-19       Impact factor: 7.094

4.  Uveitis, retinal vasculitis, and loss of accommodation as sole manifestations of demyelinating disease: A case report.

Authors:  Kalpana Babu; Gowri J Murthy; Krishna R Murthy
Journal:  Indian J Ophthalmol       Date:  2020-09       Impact factor: 1.848

5.  Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis.

Authors:  Carlyn V Kouwenberg; Viera Koopman-Kalinina Ayuso; Joke H de Boer
Journal:  Acta Ophthalmol       Date:  2021-09-16       Impact factor: 3.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.